Does the use of Pantaliv LS lead to increased risk of fractures?
Nov 5, 2023
Does the use of Pantaliv LS lead to increased risk of fractures?
Multiple adult studies have indicated a potential association between Pantaliv LS usage and an elevated vulnerability to osteoporosisrelated fractures occurring in the hip wrist or spine This risk appears to be more pronounced among patients subjected to high doses of the medication The term high dose encompasses both multiple daily administrations and prolonged treatment lasting for a year or more These findings underscore the importance of exercising caution and monitoring patients closely while considering longterm Pantaliv LS therapy It is imperative to weigh the benefits against the potential risks particularly in individuals who may already be predisposed to osteoporosis or fractures Adherence to appropriate dosage guidelines and regular assessment of bone health may be beneficial in minimizing the chances of fracture occurrence Further research is warranted to fully understand the exact nature of this association and to develop strategies for optimizing patient safety and therapeutic outcomes